Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8724386 | Osteoporosis and Sarcopenia | 2017 | 4 Pages |
Abstract
These results suggest that during denosumab therapy, the discontinuation rate is expected to remain low during 2 years of treatment in primary osteoporotic patients. In RA patients with osteoporosis, however, the discontinuation rate may increase due to economic reasons from 1 to 2 years of therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Takako Suzuki, Yukio Nakamura, Mikio Kamimura, Shota Ikegami, Shigeharu Uchiyama, Hiroyuki Kato,